Alok Srivastava on fitusiran for patients with haemophilia A and B

<p>Professor Alok Srivastava tells us about two clinical trials being published in <em>The Lancet</em> and <em>The Lancet Haematology </em>on a new siRNA therapy called fitusiran for patients with haemophilia A and B.<br/><br/>Read the two trials:<br/>Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)<br/><a href='https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext'>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext</a><br/><br/>Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B)<br/><a href='https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext'>https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext</a></p>